Representativeness of Patients Enrolled in the Lung Cancer Master Protocol (Lung-MAP).

Riha Vaidya, Joseph M Unger, Lu Qian, Katherine Minichiello, Roy S Herbst, David R Gandara, Joel W Neal, Ticiana A Leal, Jyoti D Patel, Konstantin H Dragnev, Saiama N Waqar, Martin J Edelman, Ellen V Sigal, Stacey J Adam, Shakun Malik

September 2023 JCO Precis Oncol

Synopsis of Social media discussions

The overall discussions reflect a strong recognition of the importance of including diverse populations in cancer trials, with comments highlighting that Lung-MAP enrolls more rural, older, or socioeconomically-deprived patients, citing phrases like 'a way forward' to indicate optimism about progress in equitable research. The tone emphasizes the significance of this progress but also hints at the need for continued efforts to improve representation among females and minorities.

A
Agreement
 Moderate agreement

Most discussions acknowledge that Lung-MAP improves diversity and represents a positive step in trial inclusivity, as seen with phrases like 'a way forward' and general consensus supporting broader participation.

I
Interest
 High level of interest

The social discussions focus heavily on issues of diversity, access, and trial design, which are topics of high relevance and concern in current cancer research debates.

E
Engagement
 High engagement

Many posts reference specific aspects of the study, such as increased enrollment of rural, older, or underserved populations, demonstrating active engagement and deeper analysis.

I
Impact
 Moderate level of impact

There is recognition that these findings could influence future trial designs and policies, although some posts imply that the change is ongoing and requires further action.

Social Mentions

YouTube

1 Videos

Twitter

27 Posts

News

6 Articles

Metrics

Video Views

8

Total Likes

30

Extended Reach

165,782

Social Features

34

Timeline: Posts about article

Top Social Media Posts

Posts referencing the article

Assessing Diversity in Lung Cancer Clinical Trials Through LungMAP

Assessing Diversity in Lung Cancer Clinical Trials Through LungMAP

Dr. Mary Redman discusses the LungMAP protocol's efforts to include diverse lung cancer patients, highlighting increased access for older, rural, and socioeconomically disadvantaged groups, while emphasizing ongoing challenges with racial and gender representation.

ASCO Podcasts

April 3, 2024

8 views

  • David Gandara
    @drgandara (Twitter)

    RT @LungMAP: Compared to conventional trials in advanced #NSCLC, biomarker-driven @LungMAP master protocol enrolled higher percentages of p…
    view full post

    January 9, 2024

    3

  • Cherokeeblessingway
    @CHKEBlessingway (Twitter)

    RT @LungMAP: Compared to conventional trials in advanced #NSCLC, biomarker-driven @LungMAP master protocol enrolled higher percentages of p…
    view full post

    January 8, 2024

    3

  • SWOG Cancer Research Network
    @SWOG (Twitter)

    RT @LungMAP: Compared to conventional trials in advanced #NSCLC, biomarker-driven @LungMAP master protocol enrolled higher percentages of p…
    view full post

    January 8, 2024

    3

  • Lung-MAP
    @LungMAP (Twitter)

    Compared to conventional trials in advanced #NSCLC, biomarker-driven @LungMAP master protocol enrolled higher percentages of patients who are older, from rural or socioeconomically-deprived areas, or have Medicaid or no insurance. Analysis in @JCOPO_ASCO https://t.co/jGKC3H6Lp9
    view full post

    January 8, 2024

    4

    3

  • Rafeh Naqash, MD, FASCO
    @thenasheffect (Twitter)

    RT @JCOPO_ASCO:
    view full post

    November 13, 2023

    2

  • Chidambara .ML.
    @chidambara09 (Twitter)

    RT @JCOPO_ASCO:
    view full post

    November 13, 2023

    2

  • JCO Precision Oncology
    @JCOPO_ASCO (Twitter)


    view full post

    November 13, 2023

    2

    2

  • Brian Henick
    @BHenickMD (Twitter)

    RT @LungMAP: An @JCOPO_ASCO editorial commenting on @LungMAP paper by @riharv et al: Representativeness of Patients Enrolled in the Lung…
    view full post

    November 5, 2023

    4

  • Hossein Borghaei, DO
    @HosseinBorghaei (Twitter)

    RT @LungMAP: An @JCOPO_ASCO editorial commenting on @LungMAP paper by @riharv et al: Representativeness of Patients Enrolled in the Lung…
    view full post

    November 5, 2023

    4

  • SWOG Cancer Research Network
    @SWOG (Twitter)

    RT @LungMAP: An @JCOPO_ASCO editorial commenting on @LungMAP paper by @riharv et al: Representativeness of Patients Enrolled in the Lung…
    view full post

    November 5, 2023

    4

  • Friends of Cancer Research
    @CancerResrch (Twitter)

    RT @LungMAP: An @JCOPO_ASCO editorial commenting on @LungMAP paper by @riharv et al: Representativeness of Patients Enrolled in the Lung…
    view full post

    November 5, 2023

    4

  • Lung-MAP
    @LungMAP (Twitter)

    An @JCOPO_ASCO editorial commenting on @LungMAP paper by @riharv et al: Representativeness of Patients Enrolled in the Lung Cancer Master Protocol (Lung-MAP) https://t.co/2JULwhIjAv @FNIH_Org @SWOG @CancerResrch @NCICTEP_ClinRes @HosseinBorghaei @ReckampK https://t.co/BVDNk0l07W
    view full post

    November 5, 2023

    6

    4

  • Lung-MAP
    @LungMAP (Twitter)

    RT @JCOPO_ASCO:
    view full post

    November 1, 2023

    3

  • Ticiana Batista (Leal)
    @LealTiciana (Twitter)

    RT @JCOPO_ASCO:
    view full post

    November 1, 2023

    3

  • Arthi Sridhar
    @ASridharMD (Twitter)

    RT @JCOPO_ASCO:
    view full post

    November 1, 2023

    3

  • JCO Precision Oncology
    @JCOPO_ASCO (Twitter)


    view full post

    November 1, 2023

    4

    3

  • Chidambara .ML.
    @chidambara09 (Twitter)

    RT @JCOPO_ASCO:
    view full post

    September 22, 2023

    1

  • JCO Precision Oncology
    @JCOPO_ASCO (Twitter)


    view full post

    September 22, 2023

    1

    1

  • John L.
    @MeeomHealthClub (Twitter)

    RT @SWOG: Clinical Trial #Diversity: A Bend in the Arc Toward Justice https://t.co/IQ6g9iVd7p @JCOPO_ASCO editorial says for medical evide…
    view full post

    September 21, 2023

    6

  • Elad Sharon
    @EladSharonMD (Twitter)

    RT @SWOG: Clinical Trial #Diversity: A Bend in the Arc Toward Justice https://t.co/IQ6g9iVd7p @JCOPO_ASCO editorial says for medical evide…
    view full post

    September 21, 2023

    6

  • Marie Suga, MD
    @jmsuga (Twitter)

    RT @SWOG: Clinical Trial #Diversity: A Bend in the Arc Toward Justice https://t.co/IQ6g9iVd7p @JCOPO_ASCO editorial says for medical evide…
    view full post

    September 21, 2023

    6

  • Roberta A Albany
    @raalbany (Twitter)

    RT @SWOG: Clinical Trial #Diversity: A Bend in the Arc Toward Justice https://t.co/IQ6g9iVd7p @JCOPO_ASCO editorial says for medical evide…
    view full post

    September 21, 2023

    6

  • OncoAlert
    @OncoAlert (Twitter)

    RT @SWOG: Clinical Trial #Diversity: A Bend in the Arc Toward Justice https://t.co/IQ6g9iVd7p @JCOPO_ASCO editorial says for medical evide…
    view full post

    September 21, 2023

    6

  • Lung-MAP
    @LungMAP (Twitter)

    RT @SWOG: Clinical Trial #Diversity: A Bend in the Arc Toward Justice https://t.co/IQ6g9iVd7p @JCOPO_ASCO editorial says for medical evide…
    view full post

    September 20, 2023

    6

  • SWOG Cancer Research Network
    @SWOG (Twitter)

    Clinical Trial #Diversity: A Bend in the Arc Toward Justice https://t.co/IQ6g9iVd7p @JCOPO_ASCO editorial says for medical evidence to be #equitable, we need fair #inclusion of underrepresented groups in trials: "Vaidya et al demonstrate a way forward" https://t.co/yLzWQBDJ9q
    view full post

    September 20, 2023

    13

    6

  • Medicaid Updates
    @MedicaidUpdate (Twitter)

    Date of Publication: 2023 Sep https://t.co/QjQpaWGeTG #Medicaid
    view full post

    September 8, 2023

  • Medicaid Updates
    @MedicaidUpdate (Twitter)

    Representativeness of Patients Enrolled in the Lung Cancer Master Protocol (Lung-MAP). (JCO Precis Oncol)
    view full post

    September 8, 2023

Abstract Synopsis

  • The study compares the characteristics of patients enrolled in the LungMAP master protocol for lung cancer with those in traditional NSCLC trials and the general US population, finding that LungMAP includes more older, rural, and socioeconomically deprived patients but fewer females and racial minorities.
  • Patients in LungMAP tend to be older (65+), from rural areas, or lower socioeconomic status, and there is higher enrollment of younger patients on Medicaid or without insurance, suggesting master protocols may improve access for vulnerable groups.
  • However, despite increased access for some populations, certain groups such as females and racial/ethnic minorities remain underrepresented; the research suggests that trial design and exclusion criteria influence these demographic disparities, warranting further investigation.